BNET Industries
Market Cap:$15.1B
Last Fiscal Year Sales:$15.6B
- Public
- NL
Dow Jones Description
Akzo Nobel's paint colors turn the competition green. Founded in 1911 and headquartered in Arnhem, Netherlands, Akzo Nobel N.V. (NASDAQ: AKZOY (ADR); AMS: AKZA) is the world's largest paint maker, among other businesses. The company operates in several segments. Coatings segment produces paints, stains, chemicals, auto finishes, and synthetic resins. Pharmaceuticals segment produces prescription and over-the-counter drugs. Chemicals segment produces specialty, functional, and commodity chemicals. The company has annual revenue of about ?13 billion and employs about 61,500 people. Akzo Nobel was listed on FTSE4Good Index in 2006. In 2005 it was selected as a member of the prestigious Dow Jones Sustainability Indexes, World and Stoxx.
Chairman & CEO
G.J. WijersNumber of Employees 42,600
Peer Companies
NAICS Code Medicinal and Botanical Manufacturing: 325411
Recent Events
-
2nd UPDATE: Akzo 3Q Net Profit Up, Fiscal Year Outlook Missing
-
UPDATE: AkzoNobel 3Q Net Profit Up 30%, No Full-Year Outlook Given
-
Kemira to buy Akzo Nobel's iron coagulant business in Nordic countries
-
Akzo profit a sign chemical makers have potential to surprise
-
2nd UPDATE: AkzoNobel 2Q Net 13% Down, No Fiscal Year Outlook Given
-
Akzo Nobel reports 13% decline in 2Q net income to Euro 155 million for 2009
News & Analysis
Filter by
akzo nobel n.v. and fda - All News and Analysis
Menopause treatment denied approval
- 2006-06-26
Akzo Nobel NV says that tibolone, a menopause treatment developed by its Organon unit, has been denied marketing approval by the FDA. The company notes that the product, which the company had hoped to launch in the United States under the Livial label, has been available for nearly 20 years...
Key Akzo drug launch delayed. (News Briefs).(Brief Article)
- 2002-04-17
Akzo Nobel says it will not be able to launch its new antidepression drug Ariza as expected this year, following efficacy questions by FDA. Analysts have tipped Ariza as a potential blockbuster drug with peak sales of [euro]500 million ($440 million)/year. FDA wrote to Akzo's U.S....
Sanofi's Arixtra Approved. (Markets: Life Sciences).(Sanofi-Synthelabo Inc. antithrombosis drug)(Brief Article)(Statistical Data Included)
- 2001-12-17
SANOFI-SYNTHELABO Inc. has received Food & Drug Administration FDA approval for its antithrombosis drug Aixtra fondaparinux sodium. The drug, which is being codeveloped with Akzo Nobel's Organon, will compete with Aventis' anticoagulant Lovenox enoxaparin. Merrill Lynch estimates Sanofi's consolidated sales of...
Foxboro Selected to Provide Batch Automation System for Akzo Diosource Project in the Netherlands
- 2001-02-14
Business/Technology Editors and Pharmaceutical Writers FOXBORO, Mass.--BUSINESS WIRE--Feb. 14, 2001 Akzo Nobel Engineering, Arnhem, The Netherlands, has awarded a major contract to Foxboro Nederland N.V., a unit of Invensys Process Automaton, for the automation of a new Diosynth plant at Oss in The Netherlands. The plant will be...
Akzo Gets FAD Okay.(Brief Article)
- 2000-09-11
AKZO NOBEL Polymer Chemicals LLC has obtained FDA approval for its new line of organic peroxide, Trigonox 301, used for the controlled degradation of polypropylene and in food contact applications. Trigonox 301 is the first organic peroxide to get FDA approval for those applications since Trigonox...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| R.J. Frohn | CFO |
| Rob Frohn | CFO |
| Keith Nichols | Senior Vice President, Finance |
| O. Werner | Senior Vice President, HR |
| Jan H. Dopper | Technology Director |
| John McLaren | Director, Corp Communications |
| M. Rooseboom | Senior Group Director, Coatings |
| Barry Oonk | Manager, Advertising |
| Bill McPherson | General Manager, Marine & Protective Coatings |
| Rob Molenaar | General Manager, Powder Coatings Business |
| A. Jan Eijsbouts | General Counsel |
| A.T.M. Wilderbeek | Member, Management Bd, Pharma |
| Han Jalink | Secretary |
| Leif Darner | Head |
| Rudy M.J. van der Meer | Member, Management Bd, Coatings |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| G.J. Wijers | Chairman & CEO |
| Antony Burgmans | Supervisory Board |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Chairman & CEO | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | CFO | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | CFO | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Senior Vice President, Finance | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Senior Vice President, HR | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Technology Director | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Director, Corp Communications | Current |
| Akzo Nobel N.V. | Director, Corp Communications | Former |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Senior Group Director, Coatings | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Manager, Advertising | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | General Manager, Marine & Protective Coatings | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | General Manager, Powder Coatings Business | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | General Counsel | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Member, Management Bd, Pharma | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Secretary | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Head | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Member, Management Bd, Coatings | Current |
| James Hardie Industries N.V. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Amoco Ultimate | Board of Directors | Current |
| Bp Alternative Energy | Board of Directors | Current |
| Air Bp Limited | Board of Directors | Current |
| Bp Refining and Petrochemical | Board of Directors | Current |
| Progas Limited | Board of Directors | Current |
| The Bp Group | Board of Directors | Current |
| Bp Solar Neighbors Program | Board of Directors | Current |
| Akzo Nobel N.V. | Supervisory Board | Current |
| Bp Solar International, Inc. | Board of Directors | Current |
| Bp Marine | Board of Directors | Current |
| AEGON N.V. | Supervisory Board | Current |
| BP plc | Board of Directors | Current |
| Wristore | Board of Directors | Current |
| Unilever N.V. | Business Group Vice President | Former |
| Unilever | Marketing Assistant | Former |
| Unilever N.V. | Chairman, Unilever Indonesia | Former |
| Unilever N.V. | Chairman | Former |
| Unilever N.V. | Vice Chairman | Former |
| Unilever Plc | Vice Chairman | Former |
| Unilever | Board of Directors | Former |
| University of Lancaster | MA | Former |
| Nijenrode University | Former | |
| University of Stockholm | Former |
| Volume | 1,427 |
| Shares Outstanding | 231.6M |
| Market Cap | 15.1B |
| Year High | 70.00 |
| Year Low | 32.15 |
| Earnings Per Share | -6.7840 |
| P/E Ratio | N/A |
| Dividend | 1.94 |
| Yield | 2.9575 |
Industry Transcripts by Seeking Alpha
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
Glass Door
Pharma Industry Companies
| Company | Employer Rating |
| Johnson & Johnson |  |
| Merck | |
| Pfizer | |
| Novartis |  |
| Abbott Labs | |
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
Presented by American Express